REPLIMUNE GROUP INC's ticker is REPL and the CUSIP is 76029N106. A total of 106 filers reported holding REPLIMUNE GROUP INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,788,154 | -41.5% | 221,400 | -20.6% | 0.01% | -41.2% |
| Q2 2023 | $6,478,380 | +62.2% | 279,000 | +23.4% | 0.02% | +70.0% |
| Q1 2023 | $3,992,926 | +31.2% | 226,100 | +102.1% | 0.01% | +25.0% |
| Q4 2022 | $3,043,680 | +43.6% | 111,900 | -8.8% | 0.01% | +33.3% |
| Q3 2022 | $2,119,000 | -10.3% | 122,700 | -9.2% | 0.01% | -14.3% |
| Q2 2022 | $2,363,000 | -28.6% | 135,200 | -30.6% | 0.01% | -22.2% |
| Q1 2022 | $3,309,000 | -2.5% | 194,900 | +55.7% | 0.01% | +12.5% |
| Q4 2021 | $3,393,000 | -43.1% | 125,200 | -37.7% | 0.01% | -46.7% |
| Q3 2021 | $5,958,000 | -38.0% | 201,000 | -19.6% | 0.02% | -40.0% |
| Q2 2021 | $9,609,000 | +2.8% | 250,100 | -18.4% | 0.02% | -3.8% |
| Q1 2021 | $9,348,000 | +11.0% | 306,400 | +38.8% | 0.03% | +13.0% |
| Q4 2020 | $8,424,000 | +858.4% | 220,800 | +478.0% | 0.02% | +666.7% |
| Q3 2020 | $879,000 | – | 38,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 3,050,187 | $53,866,302 | 35.13% |
| Atlas Venture Life Science Advisors, LLC | 2,098,300 | $37,055,978 | 5.02% |
| Redmile Group, LLC | 3,811,988 | $67,319,708 | 2.92% |
| Nan Fung Group Holdings Ltd | 189,339 | $3,343,727 | 2.28% |
| Altium Capital Management LP | 148,000 | $2,613,680 | 1.45% |
| Integral Health Asset Management, LLC | 395,000 | $6,975,700 | 1.40% |
| BVF INC/IL | 2,143,036 | $37,846,016 | 1.38% |
| Resolute Capital Asset Partners LLC | 82,500 | $1,457 | 1.06% |
| SECTORAL ASSET MANAGEMENT INC | 262,200 | $4,630,452 | 0.89% |
| Frazier Life Sciences Management, L.P. | 686,762 | $12,128,217 | 0.88% |